Final Decision on Sipuleucel-T


Get Permission

The Centers for Medicare & Mediaid Services (CMS) issued a final decision to cover FDA-approved indications of sipuleucel-T (Provenge) in prostate cancer, calling the treatment “reasonable and necessary.” The CMS final decision assures provider reimbursement of sipuleucel-T for Medicare beneficiaries effective immediately. Cost for the complete course of therapy is $93,000.

FDA approved sipuleucel-T in April 2010 for asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. ■


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.